Harnessing the power of RNA therapeutics in treating ischemic heart failure: the TRAIN-HEART story.

Autor:	Albert AM; Cardiac Research, Regenerative Therapies, Target Discovery & Imaging, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.; Institute for Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany., Balamurali D; Genetic Epidemiology and Statistical Genetics, Department of Biochemistry, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands., Beslika E; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.; Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal., Fernandez ID; Institute of Pharmacology and Toxicology, Technical University of Munich, Munich, Germany., Genedy HH; Université Claude Bernard Lyon 1, UMR 5223, CNRS, INSA Lyon, Université Jean Monnet, Ingénierie des Matériaux Polymères, Villeurbanne, France.; King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, London, United Kingdom., Babaei Khorzoughi R; Institute of Pharmacology and Toxicology, Technical University of Munich, Munich, Germany., Lauta FC; IRCCS Humanitas Research Hospital, Rozzano, Italy., Peppas P; Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal., Ragone I; King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, London, United Kingdom., Rizzari G; King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, London, United Kingdom., Sansonetti M; Institute for Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany., Silva J; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.; Mirabilis Therapeutics BV, Maastricht, Netherlands., Spanò G; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands., Wrona KM; Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2024 Jan 11; Vol. 10, pp. 1228160. Date of Electronic Publication: 2024 Jan 11 (Print Publication: 2023).
DOI:	10.3389/fcvm.2023.1228160
Abstrakt:	Ischemic heart disease (IHD) is one of the world's foremost killers, accounting for 16% of all deaths worldwide. IHD is the main cause of heart failure (HF), as it leads to pathological changes in the heart, improper pumping function and eventual death. Therapeutic interventions usually follow a systemic general strategy for all heart failure subtypes due to the lack of a deep understanding of the disease mechanisms. Hence, HF and IHD therapeutics need groundbreaking concepts to guide the development of a new therapeutics class that tackles the disease at a molecular level. The TRAIN-HEART consortium, a Marie Skłodowska-Curie Actions Innovative Training Network (MSCA-ITN) funded by the European Commission, was established with the goal of filling that gap and developing RNA-based cardiovascular therapeutics. Created in the context of the Horizon 2020 research and innovation program, TRAIN-HEART comprises three key work packages (WPs) focusing on the pathogenesis of heart disease (WP1), the therapeutic potential of RNA therapeutics (WP2), and the development of new efficient delivery systems (WP3). Fifteen international early stage researchers (ESRs) from multiple complementary scientific disciplines were recruited to collaborate with a network of PIs from nine academic and eight non-academic partners in various disciplines to fully harness their collective potential for the betterment of HF treatment. This article provides an overview of the benefits of being part of an MSCA-ITN, with its different training and networking opportunities, maximizing ESRs' potential and broadening collaborative research possibilities. Finally, it describes what was like to do a PhD during the COVID-19 pandemic, with all the uncertainty and concern attached to it. Luckily, TRAIN-HEART stood out as a proactive network, finding new initiatives and alternatives to promote scientific and personal development. By bringing together leading academic teams, (biotech) companies, and highly motivated researchers, TRAIN-HEART is expanding scientific horizons and accelerating future development of effective RNA-based therapies to treat IHD. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Albert, Balamurali, Beslika, Fernandez, Genedy, Babaei Khorzoughi, Lauta, Peppas, Ragone, Rizzari, Sansonetti, Silva, Spanò and Wrona.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu